孙雯娟;张波;
SUN Wenjuan;ZHANG Bo;Department of Pharmacy,Chinese Academy of Medical Sciences & Peking Union Medical College;State Key Laboratory of Complex Severe and Rare Diseases,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College;

• 1:中国医学科学院北京协和医院药剂科
• 2:中国医学科学院北京协和医院疑难重症及罕见病国家重点实验室

摘要(Abstract)：

目的 以美国为参照，对中国上市的新型抗肿瘤药物现状进行分析，探索抗肿瘤药物发展趋势，以期为抗肿瘤药品遴选提供依据。方法 检索美国食品药品监督管理局和我国国家药品监督管理局数据库，提取中国进口(美国上市)与国产自主研发的新型抗肿瘤药物的药品名称、上市时间、适应证等信息(时间截至2021年4月30日),并计算中国上市比例。结果 截至2021年4月30日，美国上市122种新型抗肿瘤药物，共覆盖14个疾病类型。其中中国进口51种，中国上市比例为41.80%。大分子单抗类药物中国上市比例最高(46.15%),其次为小分子靶向药物(44.58%),抗体药物偶联物中国上市比例最低(15.38%)。我国自2015年以来，进口新型抗肿瘤药物数量显著增多(70.59%,36/51),2015—2021年中国上市比例为50.70%(36/71),而2010—2014年中国上市比例仅为19.35%(6/31)。中国进口新型抗肿瘤药物共覆盖13个疾病类型，适应证为中国发病率前5位瘤种的新型抗肿瘤药物的中国上市比例均值为62.15%。国内自主研发的新型抗肿瘤药物共14种，包括大分子单抗类药物7种、小分子靶向药物7种，占我国现有新型抗肿瘤药物的21.54%(14/65)。其中，2015年以来上市11种(78.57%,11/14)。国内自主研发的新型抗肿瘤药物共覆盖8个疾病类型(57.14%,8/14)。结论 虽然中国新型抗肿瘤药物上市数量与美国仍有一定差距，但基本可满足临床用药需求。2015年以来，我国在加速审批、自主创新等方面持续改进。未来应从安全、疗效、经济、临床必要性等多角度对我国已上市药品与未上市药品进行考量，从而为药品遴选提供依据。
Objective To explore the trend of antitumor drugs by comparing and analyzing the novel antitumor drugs of China and US, in order to provide a basis for the selection of antitumor drugs.Methods US Food and Drug Administration and China National Medical Products Administration databases were searched, and the drug name, marketing time, indication and other information were collected(as of April 30, 2021). The proportion of listed drugs in China were calculated. Results As of April 30, 2021, there were 122 novel antitumor drugs marketed in the US, covering 14 disease types. Among them, 41.80%(51/122) were marketedin China. The proportion of monoclonal drugs was the highest(46.15%), followed by the small molecule targeted drugs(44.58%), and antibody-drug conjugate(15.38%). The number of novel antitumor drugs increased significantly(70.59%, 36/51) since 2015, and the proportion of listed drug in China from 2015 to 2021 was 50.70%(36/71), while that from 2010 to 2014 was only 19.35%(6/31). China has imported novel antitumor drugs covering 13 disease types. The average proportion of imported novel antitumor drugs for the top 5 tumors in China was 62.15%. A total of 14 novel antitumor drugs have been independently developed in China, including 7 monoclonal drugs and 7 small molecule targeted drugs, accounting for 21.54%(14/65) of the available novel antitumor drugs in China. Among them, 11 drugs(78.57%, 11/14) have been listed since 2015. The indications of novel antitumor drugs independently developed in China cover 8 disease types(57.14%, 8/14). Conclusions There are still gaps between China and US in terms of novel antitumor drugs, but these drugs can basically meet the clinical needs in China. Since 2015, China has made progress in accelerating approval and independent innovation. We should consider the safety, effectiveness, economic and clinical necessity of the listed and unlisted drugs, so as to provide a basis for drug selection in the future.

关键词(KeyWords)： 新型抗肿瘤药物;药品遴选;药物可及性;中国
novel antitumor drugs;drug selection;accessibility;China

Abstract:

Keywords:

基金项目(Foundation): 中央高水平医院临床科研业务费资助(2022-PUMCH-B-059)~~

作者(Authors): 孙雯娟;张波;
SUN Wenjuan;ZHANG Bo;Department of Pharmacy,Chinese Academy of Medical Sciences & Peking Union Medical College;State Key Laboratory of Complex Severe and Rare Diseases,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College;

参考文献(References)：

• [1] WHO.Data visualization tools for exploring the global cancer burden in 2020 [EB/OL].(2020- 01- 01)[2021- 06- 16].https://gco.iarc.fr/today/home.
• [2] 孙可欣，郑荣寿，张思维，等.2015年中国分地区恶性肿瘤发病和死亡分析[J].中国肿瘤，2019,2:1- 11.
• [3] 中华人民共和国国家卫生健康委员会.关于印发新型抗肿瘤药物临床应用指导原则(2018年版)的通知[EB/OL].(2018- 09- 21)[2021- 06- 08].http://www.nhc.gov.cn.
• [4] American Jonit Committee on Cancer.Cancer Staging Manual Eighth Edition[M].Springer Nature,2016.
• [5] WHO.Global Cancer Observatary [EB/OL].(2020- 01- 01) [2021- 06- 06].https://gco.iarc.fr/.
• [6] 国家药品监督管理局.关于解决药品注册申请积压实行优先审评审批的意见[EB/OL].(2016- 02- 26)[2021- 06- 16].https://www.nmpa.gov.cn.
• [7] 国家药品监督管理局.关于临床急需境外新药审评审批相关事宜的公告[EB/OL].(2018- 10- 23)[2021- 06- 16].https://www.nmpa.gov.cn.
• [8] Gauzy-Lazo L,Sassoon I,Brun MP.Advances in Antibody-Drug Conjugate Design:Current Clinical Landscape and Future Innovations[J].SLAS Discov,2020,25:843- 868.
• [9] 于丝雨，刘晓东，刘李.抗体药物偶联物药动学研究进展[J].药学进展，2021,45:188- 195.
• [10] Von Minckwitz G,Huang CS,Mano MS,et al.Trastu-zumab Emtansine for Residual Invasive HER2-Positive Breast Cancer[J].N Engl J Med,2019,380:617- 628.
• [11] Denevault-Sabourin C,Joubert N,Beck A,et al.Antibody-Drug Conjugates:The Last Decade[J].Pharmaceuticals,2020,13:245.
• [12] Theocharopoulos C,Lialios PP,Gogas H,et al.An over-view of antibody-drug conjugates in oncological practice[J].Ther Adv Med Oncol,2020,12:1758835920962997.
• [13] National Comprehensive Cancer Network.NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines):Chronic lymphocytic leukemia/Small lymphocytic leukemia [EB/OL].(2021- 04- 29) [2021- 06- 06].https://www.nccn.org/professionals/default.aspx.
• [14] Awan FT,Schuh A,Brown JR,et al.Acalabrutinib mono-therapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib[J].Blood Adv,2019,3:1553- 1562.
• [15] Shah A,Barrientos JC.Oral PI3K- δ,γ Inhibitor for the Management of People with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma:A Narrative Review on Duvelisib[J].Onco Targets Ther,2021,14:2109- 2119.
• [16] National Comprehensive Cancer Network.NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines):Chronic myeloid leukemia [EB/OL].(2021- 01- 13) [2021- 06- 06].https://www.nccn.org/professionals/default.aspx.
• [17] Cortes J,Lang F.Third-line therapy for chronic myeloid leukemia:current status and future directions[J].J Hematol Oncol,2021,14:2- 18.
• [18] Issa GC,DiNardo CD.Acute myeloid leukemia with IDH1 and IDH2 mutations:2021 treatment algorithm[J].Blood Cancer J,2021,11:2- 7.
• [19] Paik PK,Felip E,Veillon R,et al.Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations[J].N Engl J Med,2020,383:931- 943.
• [20] Wolf J,Seto T,Han J Y,et al.Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer[J].N Engl J Med,2020,383:944- 957.
• [21] National Comprehensive Cancer Network.NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines):Non-small cell lung cancer[EB/OL].(2021- 03- 03) [2021- 06- 26].https://www.nccn.org/professionals/default.aspx.
• [22] Drilon A,Clark JW,Weiss J,et al.Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration[J].Nat Med,2020,26:47- 51.
• [23] Camidge DR,Kim HR,Ahn MJ,et al.Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer[J].N Engl J Med,2018,379:2027- 2039.
• [24] Besse B,Solomon BJ,Felip E,et al.Lorlatinib in patients (Pts) with previously treated ALK+ advanced non-small cell lung cancer (NSCLC):Updated efficacy and safety[J].J Clin Oncol,2018,36:9032- 9032.
• [25] Murthy RK,Loi S,Okines A,et al.Tucatinib,trastuzumab and capecitabine for HER2positive metastatic breast cancer[J].N Engl J Med,2019,382:597609.
• [26] Rugo HS,Im SA,Cardoso F,et al.Efficacy of Marge-tuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer:A Phase 3 Randomized Clinical Trial[J].JAMA Oncol,2021,7:573- 584.
• [27] National Comprehensive Cancer Network.NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines):Breast cancer[EB/OL].(2021- 04- 28) [2021- 06- 26].https://www.nccn.org/professionals/default.aspx.
• [28] André F,Ciruelos E,Rubovszky G,et al.Alpelisib for PIK3CA-Mutated,Hormone Receptor-Positive Advanced Breast Cancer[J].N Engl J Med,2019,380:1929- 1940.
• [29] 赵秋玲，杨琳，谢瑞祥.9种获批上市的抗PD- 1/PD-L1单抗药物的特征综述[J].中国药房，2020,31:2294- 2299.
• [30] Hong Y,Feng Y,Sun H,et al.Tislelizumab uniquely binds to the CC' loop of PD- 1 with slow-dissociated rate and complete PD-L1 blockage[J].FEBS Open Bio,2021,11:782- 792.